MCMCB Pro
C9140

C9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.

HCPCSTerminatedBETOS O1E

C9140 is a HCPCS Level II code for injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2017 and is not valid on new claims.

This code has been terminated

CMS terminated C9140 on December 31, 2017. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.

Medicare coverage: Special coverage instructions apply

There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

The CMS record for C9140

Long descriptor
Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.

The official wording. This is what the code means.

Short descriptor
Afstyla factor viii recomb

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2017

When CMS introduced the code.

Terminated
December 31, 2017

When CMS retired it.

BETOS
O1E

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
53 — Other

Statute.

Codes adjacent to C9140

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9140 is not quite right, the correct code is very often within a few positions of it.

  • C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activityterminated
  • C9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.terminated
  • C9134Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.terminated
  • C9135Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.terminated
  • C9136Injection, factor viii, fc fusion protein, (recombinant), per i.u.terminated
  • C9137Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.terminated
  • C9138Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.terminated
  • C9139Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.terminated
  • C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.terminated
  • C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgterminated
  • C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg
  • C9144Injection, bupivacaine (posimir), 1 mg
  • C9145Injection, aprepitant, (aponvie), 1 mgterminated
  • C9146Injection, mirvetuximab soravtansine-gynx, 1 mgterminated
  • C9147Injection, tremelimumab-actl, 1 mgterminated
  • C9148Injection, teclistamab-cqyv, 0.5 mgterminated

Questions about C9140

What is HCPCS code C9140?

C9140 is a HCPCS Level II code for injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.. It sits in the Outpatient Prospective Payment System section.

Does Medicare cover C9140?

The CMS HCPCS file marks C9140 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

Is C9140 still valid?

No. C9140 was terminated on December 31, 2017 and should not be used on new claims.

HCPCS Level II2026Q3-Jul· effective July 1, 2026